论文信息 - Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study) - 字舞流文

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

M. Bauer | A. Weyland | U. Jaschinski | N. Weiler | K. Reinhart | O. Moerer | N. Riedemann | A. Nierhaus | I. Lautenschläger | G. Marx | F. Bloos | A. Jörres | M. Gründling | S. Kluge | P. Simon | T. Simon | L. Reill | S. Weber | A. Diers | R. Guo | M. Loeffler